{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:16:31Z","timestamp":1779927391183,"version":"3.53.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs), the treatment of multiple cancer types, can be associated with respiratory system adverse events (AEs). The aim of this study is to quantify the association of respiratory system AEs and ICIs and to characterize the profiles of ICI-related respiratory system complications from Food and Drug Administration Adverse Event Reporting System (FAERS) data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The disproportionality of respiratory system AE-related ICIs based on FAERS data from January 2014 to September 2021 was analyzed using the reporting odds ratio (ROR) and information component (IC) as measures of potential risk increase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 38,415,849 records were involved; among these, 36,923 records related to respiratory system AEs after ICI treatment were identified. In the first 3 months, the cumulative proportion of respiratory system AEs was 75.40%. Men had a slightly higher reporting frequency than that of women (ROR = 1.74, 95% CI: 1.70\u20131.78). Death cases had a slightly higher reporting frequency in ICI-associated respiratory system AEs than that of other drug-associated respiratory system AEs (ROR = 1.40, 95% CI: 1.38\u20131.41). Anti-programmed cell death 1 (PD-1) drugs and anti-programmed cell death ligand 1 (PD-L1) drugs were significantly associated with respiratory system toxicities. However, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) drugs did not demonstrate an association with respiratory system toxicities. Interstitial lung disease and pneumonitis were found to be significantly associated with all eight types of ICIs. In addition, 7 in 10 class-specific respiratory system AEs (lower respiratory tract disorders, pleural disorders, pulmonary vascular disorders, respiratory disorders not elsewhere classified (NEC), respiratory tract infections, respiratory tract neoplasms, and thoracic disorders) were associated with ICIs. The signal values of IC<jats:sub>025<\/jats:sub> were from 0.08 to 2.66.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, this study showed a high reporting frequency of respiratory system toxicities caused by ICIs. Early recognition and management of ICI-related respiratory system AEs are of vital importance in practice. Maximizing the benefit while reducing potential respiratory system toxicities of ICIs should become a priority.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.941079","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T07:51:26Z","timestamp":1660895486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"12","author":[{"given":"Chanjuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30167-x","article-title":"Nivolumab for classical hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/jco1801896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scienceaar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/jsemcancer201906012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0471-4","article-title":"Immuno-oncology: The third paradigm in early drug development","volume":"12","author":"Martin-Liberal","year":"2017","journal-title":"Target Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: A non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol20183923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol20162453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1750050","DOI":"10.1183\/1399300350050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco2016682005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Granulomatose sarco\u00efdosique survenant sous inhibiteurs de point de contr\u00f4le immunitaire [Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"},{"key":"B21","unstructured":"US Food and drug administration questions and answers on FDA's adverse event reporting system (FAERS)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/jlungcan201612016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12890-018-0592-x","article-title":"High incidence and early onset of nivolumab-induced pneumonitis: Four case reports and literature review","volume":"18","author":"Koyama","year":"2018","journal-title":"BMC Pulm Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1346-813812991","article-title":"Case of respiratory discomfort due to myositis after administration of nivolumab","volume":"42","author":"Yoshioka","year":"2015","journal-title":"J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/annonc\/mdx455","article-title":"Nivolumab-induced asthma in a patient with non-small-cell lung cancer","volume":"28","author":"Maeno","year":"2017","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/jchest2018081048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc202001785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: From clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc31301","article-title":"Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)","volume":"143","author":"Wu","year":"2018","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistic","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050283","article-title":"Safety of immune checkpoint inhibitors in elderly patients: An observational study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432ccr-16-1320","article-title":"PD-1 inhibitor\u2013related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/jjtho201811016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"190012","DOI":"10.1183\/160006170012-2019","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","volume":"28","author":"Delaunay","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/jjiac201707006","article-title":"Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors","volume":"23","author":"Nakahama","year":"2017","journal-title":"J Infect Chemother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/jfebslet201310015","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","volume":"588","author":"Kyi","year":"2014","journal-title":"FEBS Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.941079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T07:51:33Z","timestamp":1660895493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.941079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":37,"alternative-id":["10.3389\/fonc.2022.941079"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.941079","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"article-number":"941079"}}